Related Experiment Video
Updated: Aug 15, 2026

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes
Published on: June 16, 2011
Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse beta cells
D Miljkovic1, I Cvetkovic, M Momcilovic
1Institute for Biological Research Sinisa Stankovic, Belgrade, Serbia and Montenegro.
Abstract:
The influence of the proinflammatory cytokine interleukin (IL)-17 on inducible nitric oxide (NO) synthase (iNOS)-mediated NO release was investigated in the mouse insulinoma cell line MIN6 and mouse pancreatic islets. IL-17 markedly augmented iNOS mRNA/protein expression and subsequent NO production induced in MIN6 cells or pancreatic islets by different combinations of interferon-gamma, tumor necrosis factor-alpha, and IL-1beta. The induction of iNOS by IL-17 was preceded by phosphorylation of p38 mitogen-activated protein kinase (MAPK), and inhibition of p38 MAPK activation completely abolished IL-17-stimulated NO release. IL-17 enhanced the NO-dependent toxicity of proinflammatory cytokines toward MIN6 cells, while IL-17-specific neutralizing antibody partially reduced the NO production and rescued insulinoma cells and pancreatic islets from NO-dependent damage induced by activated T cells. Finally, a significant increase in blood IL-17 levels was observed in a multiple low-dose streptozotocin model of diabetes, suggesting that T cell-derived IL-17 might be involved in NO-dependent damage of beta cells in this disease.
Insights
Interleukin-17 (IL-17) amplifies nitric oxide (NO) production by inducing the expression of inducible NO synthase (iNOS) in pancreatic cells. This IL-17 mediated NO release contributes to beta cell damage, potentially playing a role in diabetes.
Area of Science:
- Immunology
- Endocrinology
- Molecular Biology
Background:
- Proinflammatory cytokines, including IL-17, are implicated in autoimmune diseases.
- Nitric oxide (NO) synthase (iNOS) plays a role in inflammatory responses.
- The precise role of IL-17 in iNOS-mediated NO production in pancreatic beta cells requires further elucidation.
Purpose of the Study:
- To investigate the influence of IL-17 on iNOS-mediated NO release in pancreatic beta cells.
- To explore the signaling pathways involved in IL-17-induced NO production.
- To assess the contribution of IL-17 to beta cell damage in a model of diabetes.
Main Methods:
- Experiments were conducted using the mouse insulinoma cell line MIN6 and primary mouse pancreatic islets.
- Cells were treated with combinations of interferon-gamma, tumor necrosis factor-alpha, and IL-1beta, with or without IL-17.
- iNOS expression and NO production were measured.
- p38 mitogen-activated protein kinase (MAPK) phosphorylation was assessed.
- A multiple low-dose streptozotocin model of diabetes was used to measure blood IL-17 levels.
Main Results:
- IL-17 significantly augmented iNOS mRNA/protein expression and NO production induced by other proinflammatory cytokines.
- IL-17-induced iNOS expression was dependent on p38 MAPK activation.
- IL-17 enhanced the NO-dependent toxicity of proinflammatory cytokines towards MIN6 cells.
- Neutralizing antibodies against IL-17 reduced NO production and protected cells from damage.
- Elevated blood IL-17 levels were observed in a mouse model of diabetes.
Conclusions:
- IL-17 promotes iNOS expression and NO release in pancreatic beta cells via p38 MAPK signaling.
- IL-17 contributes to NO-dependent beta cell damage.
- T cell-derived IL-17 may be involved in beta cell destruction in diabetes.

